Cel-Sci Overview
Latest ROE for Cel-Sci: -0.25% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-0.25%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Cel-Sci (CVM) currently reports a ROE of -0.25%. That is below the Healthcare sector average of 29.39%. Use the charts on this page to explore Cel-Sci's ROE history and peer comparisons.
Cel-Sci's ROE of -0.25% is lower than the Healthcare sector average of 29.39%. That is roughly 100.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Cel-Sci's current -0.25% should be judged against Healthcare norms (sector average: 29.39%) and against CVM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -0.25%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for Cel-Sci, and consider following CVM for alerts when major investors trade the stock.
Cel-Sci is classified in the Healthcare sector. On ROE, it currently shows -0.25% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CVM with unrelated industries.
